Skip to main content
Premium Trial:

Request an Annual Quote

Index Ventures Closes $300M Fund for IT, Life Science Companies

NEW YORK, July 9 – Index Ventures has closed a new $300 million fund to target information technology and life sciences companies in Europe, the firm said Monday.

A spokeswoman said the firm would target life science businesses developing post-genomic platforms, therapeutics, and nanotechnology.

Index, based in Geneva, Switzerland, would most likely devote about 30 percent of the fund to life science companies, the spokeswoman said. Index has invested in six or seven biotechnology companies in the past, including Genmab, a developer of fully-human antibodies based in Copenhagen, Denmark, and Cellzome, a functional proteomics company based in Heidelberg, Germany. 

With the current fund, Index Ventures II, the firm will focus slightly more heavily on life sciences than in the past, according to the company. Index now has a four-person team devoted to identifying early-stage life science companies.

Index invests primarily in European companies, but does consider US and Israeli companies that have early intentions to expand into Europe, or have strategic partnerships with European companies.

Investors in the current fund include UBS Capital, LGT Capital Partners, HarbourVest, and Standard Life Investments.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.